The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes.
| INTRODUCTION
BRCA1 and BRCA2 variants resulting in abrogated function of the encoded proteins confer a high risk of breast and ovarian cancer (Antoniou et al., 2003; Kuchenbaecker et al., 2017) , and have been reported to increase risk of several other cancer types (Breast Cancer Linkage C, 1999; Ford, Easton, Bishop, Narod, & Goldgar, 1994 ; Moran et al., 2012; Thompson, Easton, & Breast Cancer Linkage C, 2002) . The cancer types commonly considered important for risk assessment are breast (female and male), ovarian, prostate, and pancreatic cancer, all of which are included in the BOADICEA model predicting risk of cancer for BRCA1 and BRCA2 pathogenic variant carriers (Antoniou et al., 2008) . Identification of a pathogenic BRCA1 or BRCA2 variant is important clinical information that directs medical management of an individual, including strategies aimed at prevention (risk-reducing surgery or medication), early detection (presymptomatic screening), and more recently personalized treatment with PARP-inhibitors (Pilie, Tang, Mills, & Yap, 2019) . Further, cascade testing of close relatives of a pathogenic variant carrier is an efficient and cost-effective way to reduce the burden of cancer in individuals at high risk of developing cancer (Tuffaha et al., 2018) .
However, BRCA1 and BRCA2 variants of uncertain clinical significance (VUS) identified by diagnostic testing continue to pose a challenge for management of patients and their relatives.
ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is an international research consortium focused on developing and applying methods to determine the clinical significance in breast-ovarian cancer predisposition genes (Spurdle et al., 2012) . ENIGMA has developed variant classification criteria that utilize both quantitative (statistical) and qualitative (rules-based) methods to assess the clinical significance of variants in BRCA1 and BRCA2 (http://enigmaconsortium.org/). Quantitative classifications of variants by ENIGMA are derived from the multifactorial likelihood model (Goldgar et al., 2004; Goldgar et al., 2008) that combines multiple lines of clinical data in a Bayesian framework, with the assumption that each feature is an independent predictor of variant pathogenicity. The BRCA1/2 model components include likelihood ratios (LRs) for pathogenicity estimated from clinical data, such as co-segregation with disease, co-occurrence with a pathogenic variant in the same gene, reported family history, breast tumor pathology, and more recently, case-control data (de la Hoya et al., 2016; Easton et al., 2007; Goldgar et al., 2008; Spurdle et al., 2014; Thompson, Easton, & Goldgar, 2003) . This information is combined with a prior probability of pathogenicity based on bioinformatic predictions of variant effect on protein sequence or messenger RNA (mRNA) splicing (Tavtigian, Byrnes, Goldgar, & Thomas, 2008; Vallee et al., 2016) , probabilities that have been calibrated against clinical information, to produce a quantitative classification applicable across many variant types. It should be noted that the reference sets used to derive estimates of these LRs and prior probabilities were selected such that the model is designed to assess if a variant demonstrates the clinical features observed for a classical "high risk" variant. To date there are 297 entries on the BRCA1/2 database displaying variants classified by this method (http://hci-exlovd.hci.utah.edu/ home.php), and for which there has been publication of the breakdown of LRs for each component.
The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) developed a formal framework for using qualitative criteria for variant classification, in an attempt to standardize the application of such evidence (Richards et al., 2015) . These guidelines are intended to be generic, and thus some evidence codes will not be relevant for variant curation for a specific gene. The ClinGen consortium (Rehm et al., 2015;  https://www.clinicalgenome.org/) has engaged with expert groups to develop adaptations of the guidelines to specify which rule codes and strengths are appropriate for a specific genedisease relationship, and to provide guidance on the phenotypic features that are most predictive of variant pathogenicity (Rivera-Munoz et al., 2018) . To date, adaptations of the ACMG/AMP criteria have been completed for two hereditary cancer genes: PTEN (Mester et al., 2018) and CDH1 , whereas other geneadaptations are in development. In addition, ClinGen has approved two additional expert panels arising from pre-existing international research consortia, for the curation of variants in the mismatch repair genes (InSiGHT, International Society for Gastrointestinal Hereditary Tumours; https://www.insight-group.org), and in BRCA1 and BRCA2 (ENIGMA; http://enigmaconsortium.org/). The classification criteria used by these groups pre-dated the development of ACMG/AMP adaptations, and use quantitative methods (as noted above) and qualitative criteria not yet cross-mapped to ACMG/AMP codes. The ClinGen Sequence Variant Interpretation Working Group recently demonstrated that the ACMG/AMP criteria were broadly compatible with Bayesian statistical reasoning, and estimated LR ranges appropriate for code strengths (Tavtigian et al., 2018) .
Reference data is essential to calibrate the appropriate genespecific strength of different curation evidence types, and also to assess if evidence strength is the same for variants with different molecular effects. In relation to BRCA1 and BRCA2, most variants established to be pathogenic are premature truncation variants (including nonsense or frameshift), and thus comprise the majority of variants in reference sets used to calibrate predictors of BRCA1/2 variant pathogenicity. We have collated data from >40 clinical sites within ENIGMA and from other international clinical collaborators to conduct the largest application of the multifactorial likelihood model to missense and intronic variants in BRCA1 and BRCA2, providing quantitative variant classifications, and also scores for the component data types so as to demonstrate their relative contributions to the final posterior probability. We have also demonstrated the value of this dataset as a resource for calibrating qualitative information for application to BRCA1/2 variant classification, and deriving BRCA1/ 2-appropriate rule strengths for several ACMG/AMP evidence codes.
| METHODS

| Variant selection for data collection
At the time of joining ENIGMA, members were asked to submit all variants in BRCA1 and BRCA2 that they considered to be of uncertain clinical significance, together with the number of families carrying each variant. We followed the rationale that high-risk variants will not occur commonly in the general population, as indicated by frequency measured in outbred reference datasets representative of subpopulations. Variants were thus classified as Class 1 Not Pathogenic if they were identified to occur at minor allele frequency >0.01 in one or more of the following datasets: (Michailidou et al., 2013) . Variants included in the iCOGS project were prioritized for genotyping using the same approach as for the baseline ENIGMA variant list, with additional variants selected due to laboratory/bioinformatic evidence for effect on mRNA splicing.
For each variant, a positive control DNA from a variant carrier was submitted for genotyping to facilitate calling of these rare variants.
Lastly, we included a subset of variants for which multifactorial likelihood analysis results had previously been published, but the final classification reported was not "Class 5 Pathogenic" or "Class 1 Not Pathogenic", and/or LRs were not all visible in the original publication (Easton et al., 2007; Farrugia et al., 2008; Lindor et al., 2012) . Information from all these sources was collated for a total of 3,295 variants. This amalgamated list of variants was then circulated by email to ENIGMA consortium members to invite them to provide additional segregation or pathology information for inclusion in the analysis. Where relevant, additional nonoverlapping pathology or segregation information was sourced directly from publications for inclusion in the analysis. Overall, there were 1,008 informative pathology data points and 895 informative families for segregation analysis from ENIGMA collaborators, clinical enquiries, and nonoverlapping publications (see below for further explanation about LR assignment). After combining all information, at least one data point was available for 1,395 variants. PARSONS ET AL.
| 1563
Variant descriptions are in accordance to HGVS recommendations. Nucleotide numbering corresponds to reference transcripts NM_007294.3 (BRCA1) and NM_000059.3 (BRCA2). Legacy description is also provided to assist comparison with historical records in the literature; the nucleotide numbering is from nucleotide one of the full gene sequence (Genbank: U14680.1/BRCA1; U43746/BRCA2) not the ATG initiator codon, and BRCA1 exon boundaries are from GenBank U14680.1 with exon four missing due to a correction made after the initial description of the gene.
| Multifactorial likelihood analysis
A Bayesian model was used to combine evidence as previously described . In brief, the prior probability of pathogenicity was assigned based on a combination of Align-GVGD score and MaxEntScan splicing predictions, overlaid with expert knowledge incorporating prediction of variant effect on critical functional protein domains Vallee et al., 2016) .
Applicable prior probability of pathogenicity predictions for single nucleotide variants in BRCA1 and BRCA2 are available from the HCI Database of Prior Probabilities of Pathogenicity for Single Nucleotide Substitutions (http://priors.hci.utah.edu/PRIORS/). Align-GVGD does not score in-frame insertions and deletions, therefore to estimate prior probabilities for in-frame deletion variants studied, we took the highest Align-GVGD prior of the deleted bases. There were no inframe exonic insertions included in this study. The higher of the two priors (missense vs. splicing) was assigned for analysis. Co-segregation analysis was performed as described by Thompson et al. (2003) for each family with more than one individual genotyped for the variant. Hazard ratio estimates were taken from Antoniou et al. (2003) for <30, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ age brackets. For individuals affected with ovarian cancer at 20-29 years, penetrance for ovarian cancer at age 30-39 was applied due to a lack of information in the younger penetrance class (Antoniou et al., 2003) . If no age at last update was provided by the submitting center for unaffected individuals, test date was used to infer current age.
Breast tumor pathology LRs were assigned based on the estimates in Spurdle et al. (2014) , and considered age at diagnosis. When multiple tumors were present in one individual, the first diagnosed tumor with information available was taken, and only a single LR was assigned according to the extent of information available (out of the variables tumor grade, ER, PR, and HER2), following previous recommendations . Likelihood ratios for co-occurrence with a pathogenic variant (in trans), and reported family history analysis, were drawn from a previous publication (Easton et al., 2007) .
Case-control data from the iCOGS project were used to estimate LRs following methods described previously (de la Hoya et al., 2016) . Table S2 .
It has previously been proposed that a combined LR between 0.5 and 2, in particular if derived from a limited number of data points, provides insufficient observational data to perform a valid integrated analysis (Vallee et al., 2016) . This is in accord with the idea that ACMG guidelines intrinsically include an indeterminate zone, between supporting benign and supporting pathogenic, for variants with insufficient or conflicting evidence for pathogenicity. Following this rationale, posterior probabilities of pathogenicity were not calculated for any variant with a combined LR between 0.5 and 2.
Posterior probability of pathogenicity was calculated for a total of 734 variants, and classification assigned based on previously published cut-offs proposed for the International Agency for Research into Cancer (IARC) five tier classification scheme (Plon et al., 2008) , with some modification of terms used to describe tiers (Spurdle et al., 2019) 
| mRNA splicing assay data
Published mRNA splicing assays of BRCA1 and BRCA2 variants were collated for a previous ENIGMA project (Walker et al., 2013) , a resource which has been updated over time. Details of transcripts observed were recorded, and nomenclature errors for variant and transcripts corrected as necessary. We matched these results against the 1,395 variants included in this study (Table S1 ). Assays that provided variant allele-specific transcript results from patient-derived mRNA were noted as being eligible for assessment according to the ENIGMA classification guidelines, and effect on mRNA splicing was coded as none, partial, or complete (column Coded Splicing Effect). All other assay results (including additional assays of patient mRNA that did not measure allele-specific expression, and construct-based assays), were noted as to whether the variants were reported to impact mRNA splicing profile or not (column Allele-Specific Splicing Result Summary). To simplify comparison with broad ACMG code description, the relationship of aberrant transcript/s to protein effect that is premature termination, disruption of clinically important residues was not captured in the mRNA effect codes. Further, to limit these LR measures to variant effect on mRNA splicing only, variants classified as (Likely) Pathogenic that had high bioinformatic prediction of effect on amino acid sequence were presumed to confer pathogenicity via effect on protein function, and excluded from the reference set for derivation of the mRNA splicing LRs. See Table S3 for details of the variants included in mRNA splicing subanalysis, and code assignments.
| Protein functional assay data
Seven relatively recent publications, providing results from different mammalian-based assays of protein function, were chosen for comparison with classifications arising from multifactorial analysis. (Petitalot et al., 2019) . These selected studies were the most recent publications arising from these research groups, and incorporated research results from any prior publications from that group. Two additional publications were selected as they provide results from high-throughput multiplex assays. The first was a multiplex reporter assay characterizing the effects of 1,056 amino acid substitutions in the first 192 residues of BRCA1 on homologydirected repair of double strand breaks (Starita et al., 2018) . The second was a high-throughput saturation genome editing haploid cell survival assay, measuring functional effect for single nucleotide variants in 13 BRCA1 exons covering key functional domains (Findlay et al., 2018) : targeted genomic DNA sequencing and RNA sequencing were used to quantify variant abundance and infer effect on BRCA1 function overall (DNA sequencing), and via effect on mRNA production (RNA sequencing); function scores for different exons were normalized by matching median scores for synonymous and nonsense variants to global medians for these variant types. The assay design for five of the seven studies permitted assay of effect on protein only, and not mRNA levels or splicing. We thus excluded "missense" variants that were known to alter mRNA levels or splicing, or were located in the splicing motifs at the start/end of exons, such that comparisons with results from functional studies should all be limited to measures of variant effect on protein only. Effect on function as assigned by the original publication was recoded into one of three tiers (complete, partial, or no functional impact). A total of 77 unique variants assayed by at least one study were available for comparison with multifactorial likelihood classifications. See Table S4 for details of the variants and functional code assignments. For Table 1b of the publication (Petitalot et al., 2019 ).
| Reference population frequency data
Population frequency data were downloaded from the Genome Aggregation Database (gnomAD non-cancer v2.1 dataset; gnomad .broadinstitute.org). Three large in-frame deletion variants classified as Pathogenic were excluded from the population frequency LR estimation analysis, as frequencies are not provided by gnomAD for variants of this type. No large deletion variants were classified as (Likely)
Benign. As an exercise to compare the validity of gnomAD as a "control" reference dataset, we also compared the frequency of 17 variants detected at allele frequency <1% in European ancestry breast cancer-free controls (n = 38,694) genotyped as part of iCOGS, to frequencies for the same variants observed in (a) non-Finnish Europeans from gnomAD (maximum n = 59,073, from genome and exome data combined), and (b) European aged (>70 year old) cancerfree control from the FLOSSIES dataset (n = 7,325; https://whi.color. com/). Our comparisons of variant frequency in gnomAD to those of "true" controls of European ancestry (Table S5 ) indicated that variants were more likely to be absent from the smaller FLOSSIES dataset (only 6/17 variants were observed), whereas the frequency category based on the gnomAD non-Finnish Europeans was the same as that for iCOGS European ancestry controls for all 17 variants. The FLOSSIES PARSONS ET AL.
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African dataset provides allele frequencies based on 2,559 individuals (5,118 alleles), which is considerably smaller than the gnomAD African dataset. For this reason we opted to use only gnomAD outbred (nonfounder) sample sets 174] , African [8, 620] , Latino [22, 108] , South Asian [21, 526] , East Asian [14, [12] [13] [14] [15] [16] [17] [18] [19] 252] ) to determine the highest minor allele frequency observed based on exome and genome data combined. Variants observed only once across all five outbred sample sets were annotated as such for frequency LR estimation (Table S1 ). Variants absent from all five outbred sample sets, but present once in Finnish or Ashkenazi Jewish sample sets were excluded from the frequency LR estimation (noted as "NA" in column "Frequency Category Assigned for LR derivation" in Table S1 ).
Designation of LRs to ACMG/AMP rule code strengths were based on LR ranges recently proposed as consistent with ACMG/ AMP qualitative rule strengths for future classification in a Bayesian framework (Tavtigian et al., 2018) . Namely: supporting evidence for pathogenicity, LR 2.08-4.3; moderate evidence for pathogenicity, LR 4.3-18.7; and strong evidence for pathogenicity; LR 18.7-350. LRs ranges for Benign code strengths were calculated as the inverse of the ranges proposed for Pathogenic code strengths.
| RESULTS AND DISCUSSION
An IARC class informative for clinical management (Class 1 Benign, Class 2 Likely Benign, Class 4 Likely Pathogenic, or Class 5 Pathogenic) was reached for 541/734 (74%) of the 734 variants considered to have sufficient information to inform calculation of a posterior probability of pathogenicity (Table S1 ). The remaining 193/734 variants fell within the wide range of 0.05-0.95 considered inconclusive of variant pathogenicity (Class 3 Uncertain). Overall, only 54 of the 541 variants with posterior probability assigned have previously been assessed using the multifactorial likelihood approach, and in some instances the clinical evidence included previously did not pass thresholds that have since been set for combined LR (between 0.5 and 2) considered informative for quantitative analysis (see Methods). Of the 541 variants falling (Table 1) , with 447 (61%) classified as (Likely) Benign. These findings are consistent with the knowledge that the majority of missense and intronic variants in these genes will, a priori, not be associated with a high risk of cancer as they fall outside of or are unlikely to impact BRCA1 or BRCA2 protein functional domains.
Further, we draw attention in particular to two variants (BRCA2 c.516+1G>T and BRCA2 c.7007+1G>C) demonstrating differences between multifactorial likelihood-based analysis and the current iteration of ENIGMA "rules-based" qualitative assessment based on mRNA splicing assay data from patient material (Houdayer et al., 2012; Whiley et al., 2011) . The splicing assay data, albeit not allelespecific, indicate that both variants impact splicing profile. According to ENIGMA qualitative classification criteria, the BRCA2 c.516+1G>T 
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Namely, a variant is only considered pathogenic on the basis on mRNA splicing data if there is no predicted functional transcript produced from the variant allele, as determined by assays of patientderived mRNA that have assessed allele-specific expression of alternate transcripts. This stipulation is not specified for ACMG/ AMP classification codes using splicing data (PS3, well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product).
We undertook a comparison of multifactorial model classifications against published splicing assays results (including assays of patient material and construct-based assays) to calibrate use of splicing assay data for use as weighted information for qualitative classification, based on the LR ranges recently proposed as consistent with ACMG/AMP qualitative rule strengths for future classification in a Bayesian framework (Tavtigian et al., 2018) . Of the variants falling outside of Class 3 Uncertain in this analysis, 99 had mRNA splicing data available, 25 of which had been assessed using allelespecific assays of mRNA from patient tissue. By comparing splicing effect to classifications derived from this study, we estimated a LR towards pathogenicity based on effect on mRNA splicing (Table 2 ; Table S3 for additional details). The very limited number of allelespecific assays did not allow for robust estimates of LRs, with the confidence intervals for LRs estimated for both partial and complete effect on splicing including unity. Nevertheless, results support the hypothesis that partial effect on splicing will not be as strongly predictive of pathogenicity as is complete effect on splicing (LR 3.82 vs. LR 6.36 from this analysis). Including all assay results, no effect on splicing provided strong evidence against pathogenicity (LR 0.02),
whereas any impact on splicing (without measurement of allelespecific effects, or consideration of in-frame transcripts) provided moderate evidence for pathogenicity (LR 12.24) . Recognizing the small sample sizes, and consequently large confidence limits, these results nevertheless demonstrate the value of mRNA splicing assays as a component in qualitative variant classification. We also highlight the possibility that there is likely to be considerable bias in variants selected for mRNA assays, with over-representation of variants at the highly conserved donor and acceptor dinucleotides, positions that, when altered, are likely to impact splicing more severely than spliceogenic variants located at other positions. We thus stress the importance of incorporating allele-specific expression assays into variant evaluation processes wherever possible, and to revisit such analysis with larger datasets in the future. We also recommend that Pathogenic assertion based on splicing data only. previously been determined to be pathogenic or benign (Guidugli et al., 2014; Millot et al., 2012) ; that is assay profiles for truncating variants may not be appropriate to measure loss of function displayed by pathogenic missense variants. To prevent circularity, functional assay results should not have contributed to the classification of these "control" missense variants, as may be the situation for variants submitted to ClinVar as pathogenic. An additional factor to consider, but not addressable at this point in time, is that there are few BRCA1/2 variants robustly proven to be associated with moderate risk of cancer. There is thus a paucity of controls to calibrate assay results to detect moderate-risk variants.
| Correlation of multifactorial likelihood classifications with protein functional assay data
Moderate-risk variants are intuitively expected to have less impact on function than variants associated with a high cancer risk comparable to that of the average truncating allele, and severity of their impact on function may differ depending on the specific protein effects measured (Lovelock et al., 2007) . 
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For this reason, we compared our multifactorial analysis results for missense variants classified outside of Class 3 Uncertain to results from selected published functional assays (also see Methods).
Briefly, these included: (a) domain-specific or generic assays assessing variant effect on protein function, and calibrated against missense variants previously classified as pathogenic or benign using multifactorial likelihood analysis that is using bioinformatic and clinical information (Bouwman et al., 2013; Fernandes et al., 2019; Hart et al., 2019; Mesman et al., 2019; Petitalot et al., 2019) ; and (b) multiplex reporter assays (Findlay et al., 2018; Starita et al., 2018) reported to have reasonable to good sensitivity and specificity by comparison to ClinVar classifications (including truncating, splicing, and missense variants). There were 16 (Likely) Pathogenic and 61 (Likely) Benign variants with a protein functional assay result from at least one study (Table 3 ; Table S4 for additional details). All 56 variants reported to have no functional impact were classified as p.(Arg2784Gln) did complement lethality in the mouse embryonic stem cell assay (Mesman et al., 2019) , but was coded as impacting function based on homologous recombination assay results from the same study (Mesman et al., 2019) , and was reported to impact homologous recombination in an independent study (Hart et al., 2019) . We note that for the two exceptions highlighted (BRCA1 c.5216A>T, BRCA2 c.8351G>A), the results from survival assays were concordant with the multifactorial likelihood classification.
Considering results overall, we estimated a LR towards pathogenicity based on assays of protein function from at least one study (Table 3) .
Acknowledging the caveat of small sample sizes, and at least one (MAF) > 1% in a nonfounder population is considered stand-alone evidence against pathogenicity for BRCA1/2 variants by the ENIGMA consortium. An algorithm to define a "maximum credible population allele frequency" (Whiffin et al., 2017) has been proposed as a method to select MAF cut-offs as evidence against pathogenicity, and indeed was used as a basis to select relevant minor allele frequency cut-offs for the PTEN and CDH1 adaptations of ACMG/AMP rule codes BA1 (stand-alone) and BS1 (strong) evidence against pathogenicity, described as "allele frequency is greater than expected for the disorder." The output of this algorithm can vary widely depending on input assumptions for disease penetrance and prevalence of the disorder, and is complicated for multicancer syndromes where penetrance varies for cancer type and even cancer subtype. Further, absence from control datasets has been proposed as moderate evidence for variant pathogenicity (ACMG/AMP rule code PM2).
The most commonly used "control" reference sets (ExAC, and more recently gnomAD) include males and females that were ascertained for noncancer related studies mostly at ages younger than the average age at onset of BRCA1/2-related breast or ovarian cancer, but individual-level information about cancer phenotypes is not available. Even assuming that these reference sets are largely cancer unaffected, it must be considered that penetrance in female pathogenic variant carriers for breast cancer is not complete, and much lower for male carriers. Indeed, known pathogenic BRCA1/2 variants have been identified in these population control sets, even after accounting for "founder" pathogenic variants (Maxwell, Domchek, Nathanson, & Robson, 2016 To determine the utility of variant frequency in (or absence from) reference population sets for future BRCA1 and BRCA2 variant classification, and to formally assess the strength of this evidence, we estimated a LR based on MAF in gnomAD v2.1 (noncancer), and considered them against LR cut-offs suggested for ACMG/AMP rules (Tavtigian et al., 2018) . Results are shown in Overall, these findings, based on empirical data, have utility to inform the ongoing adjustment of the ENIGMA BRCA1/2 guidelines.
Use of these frequency cut-offs for variants designated in this study ( showed that use of clinical information, when available, provides significant improvements to variant classification over purely bioinformatic approaches. In addition to the CAGI 5 experiment, we chose to use an updated dataset for calibration of isolated data types commonly used as components of qualitative classification approaches. Specifically, the variant classifications from multifactorial likelihood analysis were derived without use of laboratory splicing and functional data, or variant frequency in outbred reference populations. This allowed us to estimate independent LRs for or against pathogenicity for these evidence types, with several purposes: to assess the validity of ACMG/AMP code strengths proposed for these evidence types when applying them to classification of BRCA1/2 variants; to justify specific ENIGMA BRCA1/2 classification criteria incorporating population frequency or mRNA splicing data; to provide guidance on incorporation of BRCA1/2 protein functional assay data, to assess BRCA1/2 predicted missense variants specifically, in quantitative or qualitative (rules-based) classification models. We acknowledge that further analyses are necessary before such LR estimations be formally reviewed and incorporated into guidelines for BRCA1/2 Expert Panel variant interpretations. Namely, it will be important to investigate LR estimations with additional variants that have been previously assessed using the multifactorial likelihood approach, and to derive LRs separately for BRCA1 and BRCA2 given differences in the penetrance for truncating variants in these two genes and the potential for differences in sensitivity and specificity of different laboratory assays to detect impact on function. Nevertheless, we note that, despite the fact that known BRCA1/2 pathogenic variants are seen in reference population datasets, and acknowledging reservations that absence in control populations overall is not a predictor of variant pathogenicity, it appears that this feature does have value for examining the clinical relevance of rarer variants presenting for assessment at this point in time; that is, accounting for the fact that "known pathogenic" variants observed in control datasets are more likely to have already been observed in the clinical setting and already classified using other information types.
This observation highlights issues around constancy of evidence strengths over time, and indicates that it will be important to reconsider such analysis periodically to re-estimate LRs and corresponding rule strengths as the pool of variants remaining to be classified alters over time. Following this line of thought, it will be important that estimates of prior probability based on bioinformatic predictions are re-estimated using updated datasets that reflect changed variant pools, and altered patient ascertainment in the era of multigene panel testing. Results arising from the CAGI 5 experiment (Cline et al., ) , and other similar studies, are likely to inform development of such bioinformatic methods.
In summary, we have used the multifactorial likelihood analysis approach to generate 248 new or considerably altered BRCA1/2 variant classifications, information that is relevant for medical managementincluding determining patient eligibility for screening or PARPi treatment, and cascade testing of their relatives. We have also shown the value of this dataset for confirming existing ClinVar assertions, and for calibration of additional data types useful for variant interpretation.
We have provided as supplementary information details regarding data sources and likelihood scores for all variants investigated, so providing a resource that will facilitate continued assessment of variants as additional information accrues, and further calibration of new lines of evidence relevant for variant interpretation.
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